Table 2.
Quantification of kif21b expression in situ
| Patient id | Age at death | Gender | Presenting symptom | Time to EDSS 6.0 (years) | Neuropathology assessment | Kif21b1 | Kif21b genotype | ||
|---|---|---|---|---|---|---|---|---|---|
| Braak stage | Amyloid | Neu-rons | Glia cells | ||||||
| NDC2 | 49 | F | NA | NA | 0 | ND | + | - | GA |
| NDC4 | 53 | F | 0 | 0 | +/- | - | GA | ||
| NDC6 | 56 | F | 0 | 0 | +/- | - | GG | ||
| NDC8 | 62 | F | 1 | 0 | +/- | - | GA | ||
| NDC10 | 70 | F | 0 | B | + | + | GA | ||
| NDC13 | 50 | M | 1 | 0 | - | - | AA | ||
| NDC29 | 77 | M | 1 | B | +/- / + | - | GG | ||
| NDC30 | 78 | M | 1 | A | +/- | +/- | AA | ||
| NDC36 | 82 | M | 1 | A | +/- | - | GG | ||
| MS4 | 50 | F | Myelitis | 7 | ND | ND | - | - | GG |
| MS6 | 56 | F | ND | 4* | ND | ND | + | + | GG |
| MS8 | 63 | F | Optic neuritis | 17 | 0 | 0 | + | - | GA |
| MS10 | 70 | F | Cerebrum | 30 | 1 | 0 | - | - | GG |
| MS23 | 56 | M | Myelitis | 2 | ND | ND | - | - | AA |
| MS25 | 57 | M | Myelitis | 6 | ND | ND | +/- | - | GG |
| MS40 | 74 | M | Myelitis | 8 | 3 | 0 | - | - | AA |
| AD2 | 57 | F | NA | NA | 6 | C | + | +/- | GA |
| AD4 | 57 | F | 6 | C | + | - | GG | ||
| AD6 | 59 | F | 5 | C | +/++ | +/++ | GA | ||
| AD8 | 63 | F | 5 | C | +/- | - | GG | ||
| AD10 | 70 | F | 5 | C | + | - | GA | ||
| AD13 | 42 | M | 6 | C | +/- | +/- | AA | ||
| AD15 | 54 | M | 6 | C | + | +/- | AA | ||
| AD20 | 58 | M | 4 | C | ++ | ++ | GG | ||
| AD42 | 76 | M | 5 | C | + | +/- | GA | ||
In age-, gender- and genotyped matched MS and AD patients, kif21b protein expression was assessed. NA not applicable, ND not determined or documented.
1scored as: - no positive cells, +/-1-2 positive cells per field, + maximum of ~30% of the cells positive, ++ ~60% of the cells positive, +++ ~80% positive cells and +++ (virtually) all cells positive.
*time to EDSS 9.0.
Neuropathology assessment based on Braak criteria [12].